Principles in the design of ligand-targeted cancer therapeutics and imaging agents

Nature Reviews Drug Discovery

Volumn 14, Issue 3, 2015, Pages 203-219

  Srinivasarao, Madduri ^a   Galliford, Chris V ^a   Low, Philip S ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANG 1005; ANTINEOPLASTIC AGENT; BIND 014; BOMBESIN RECEPTOR; CD24 ANTIGEN; CELL SURFACE RECEPTOR; CHOLECYSTOKININ B RECEPTOR; DOCETAXEL; DOXORUBICIN; EC 0225; EC 0489; EC 1456; EC 17; EDOTREOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPOFOLATE; ETARFOLATIDE TC 99M; GELATINASE A; GLUFOSFAMIDE; INDIUM 111; LIGAND; LIPOSOME; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; POLYMER; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR 2; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINTAFOLIDE; CONTRAST MEDIUM;

BINDING AFFINITY; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG METABOLISM; DRUG POTENCY; DRUG RELEASE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENDOCYTOSIS; ENDOMETRIUM CANCER; HUMAN; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; STRUCTURE ANALYSIS; ANIMAL; NEOPLASMS; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIGANDS; NEOPLASMS;

EID: 84924094144     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4519     Document Type: Review

References (213)

1. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nature Rev. Cancer 2, 750-763 (2002).
2. van der Meel, R., Vehmeijer, L. J., Kok, R. J., Storm, G. & van Gaal, E. V. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv. Drug Deliv. Rev. 65, 1284-1298 (2013).
3. Chari, R. V. J., Miller, M. L. & Widdison, W. C. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew. Chem. Int. Ed. 53, 3796-3827 (2014).
4. Wang, A. Z. & Farokhzad, O. C. Current progress of aptamer-based molecular imaging. J. Nucl. Med. 55, 353-356 (2014).
5. Zhang, X. et al. A cell-based single-stranded DNA aptamer specifically targets gastric cancer. Int. J. Biochem. Cell Biol. 46, 1-8 (2013).
6. Yu, B., Tai, H. C., Xue, W., Lee, L. J. & Lee, R. J. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol. Membr. Biol. 27, 286-298 (2010).
7. Shahied, L. S. et al. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J. Biol. Chem. 279, 53907-53914 (2004).
8. Kurzrock, R. et al. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol. Cancer Ther. 11, 308-316 (2012).
9. Zhang, X. X., Eden, H. S. & Chen, X. Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates. J. Control Release 159, 2-13 (2012).
10. Rana, S. et al. Screening of a novel peptide targeting the proteoglycan-like region of human carbonic anhydrase IX. Mol. Imag. 12, 497-509 (2013).
11. McGuire, M. J. et al. Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer. Sci. Rep. 4, 4480 (2014).
12. Xia, W. & Low, P. S. Folate-targeted therapies for cancer. J. Med. Chem. 53, 6811-6824 (2010).
13. Varghese, B. et al. Folate receptor-β in activated macrophages: ligand binding and receptor recycling kinetics. Mol. Pharm. 11, 3609-3616 (2014).
14. Vaitilingam, B. et al. A folate receptor-α-specific ligand that targets cancer tissue and not sites of inflammation. J. Nuclear Med. 53, 1127-1134 (2012).
15. Thomas, M. et al. Ligand-targeted delivery of small interfering RNAs to malignant cells and tissues. Ann. NY Acad. Sci. 1175, 32-39 (2009).
16. Shen, J., Chelvam, V., Cresswell, G. & Low, P. S. Use of folate-conjugated imaging agents to target alternatively activated macrophages in a murine model of asthma. Mol. Pharm. 10, 1918-1927 (2013).
17. Sassoon, I. & Blanc, V. Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol. Biol. 1045, 1-27 (2013).
18. Ducry, L. Antibody-Drug Conjugates. (Humana Press, 2013).
19. Bander, N. H. Antibody-drug conjugate target selection: critical factors. Methods Mol. Biol. 1045, 29-40 (2013).
20. Haddley, K. Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer. Drugs Today 49, 701-715 (2013).
21. Perini, G. F. & Pro, B. Brentuximab vedotin in CD30+ lymphomas. Biol. Ther. 3, 15-23 (2013).
22. Trapani, G., Denora, N., Trapani, A. & Laquintana, V. Recent advances in ligand targeted therapy. J. Drug Target. 20, 1-22 (2012).
23. Liu, X. et al. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin. Vaccine 30, 6527-6533 (2012).
24. Jeannin, P. et al. Immunogenicity and antigenicity of synthetic peptides derived from the mite allergen Der p I. Mol. Immunol. 30, 1511-1518 (1993).
25. Adem, Y. T. et al. Auristatin antibody drug conjugate physical instability and the role of drug payload. Bioconjug. Chem. 25, 656-664 (2014).
26. Zimmerman, E. S. et al. Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. Bioconjug. Chem. 25, 351-361 (2014).
27. Behrens, C. R. & Liu, B. Methods for site-specific drug conjugation to antibodies. MAbs 6, 46-53 (2014).
28. Firer, M. A. & Gellerman, G. Targeted drug delivery for cancer therapy: the other side of antibodies. J. Hematol. Oncol. 5, 1756-8722 (2012).
29. Jain, R. K. & Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nature Rev. Clin. Oncol. 7, 653-664 (2010).
30. Yuan, F. et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752-3756 (1995).
31. Weinstein, J. N. & van Osdol, W. Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier". Cancer Res 52, 2747s-2751s (1992).
32. van Osdol, W., Fujimori, K. & Weinstein, J. N. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier". Cancer Res. 51, 4776-4784 (1991).
33. Lee, H., Fonge, H., Hoang, B., Reilly, R. M. & Allen, C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol. Pharm. 7, 1195-1208 (2010).
34. Kostarelos, K. et al. Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int. J. Cancer 112, 713-721 (2004).
35. Juweid, M. et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 52, 5144-5153 (1992).
36. Shin, G. et al. GENT: gene expression database of normal and tumor tissues. Cancer Informat. 10, 149-157 (2011).
37. Rhodes, D. et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1-6 (2004).
38. Mitchison, T. J. The proliferation rate paradox in antimitotic chemotherapy. Mol. Biol. Cell 23, 1-6 (2012).
39. Paulos, C. M., Reddy, J. A., Leamon, C. P., Turk, M. J. & Low, P. S. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol. Pharmacol. 66, 1406-1414 (2004).
40. Bandara, N. A., Hansen, M. J. & Low, P. S. Effect of receptor occupancy on folate receptor internalization. Mol. Pharm. 11, 1007-1013 (2014).
41. Seshadri, R. et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. South Australian Breast Cancer Study Group. J. Clin. Oncol. 11, 1936-1942 (1993).
42. Brune, V. et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J. Exp. Med. 205, 2251-2268 (2008).
43. Eckerle, S. et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia 23, 2129-2138 (2009).
44. Rose, A. A. et al. Osteoactivin promotes breast cancer metastasis to bone. Mol. Cancer Res. 5, 1001-1014 (2007).
45. Zhou, L. T. et al. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy. Neoplasma 59, 1-5 (2012).
46. Abou-Bakr, A. A. & Elbasmi, A. c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma. Gulf J. Oncolog. 1, 28-34 (2013).
47. Mesteri, I., Schoppmann, S. F., Preusser, M. & Birner, P. Overexpression of cMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma. Eur. J. Cancer 50, 1354-1360 (2014).
48. Fost, C. et al. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. Oncol. Rep. 25, 1481-1487 (2011).
49. Ries, J. et al. The relevance of EGFR overexpression for the prediction of the malignant transformation of oral leukoplakia. Oncol. Rep. 30, 1149-1156 (2013).
50. Parker, N. et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 338, 284-293 (2005).
51. Wang, X., Ma, D., Olson, W. C. & Heston, W. D. W. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol. Cancer Ther. 10, 1728-1739 (2011).
52. Kinet, S. et al. Isolated receptor binding domains of HTLV-1 and HTLV-2 envelopes bind Glut-1 on activated CD4+ and CD8+ T cells. Retrovirology 4, 31 (2007).
53. Saul, J. M., Annapragada, A., Natarajan, J. V. & Bellamkonda, R. V. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J. Controlled Release 92, 49-67 (2003).
54. Crane, L. M. et al. The effect of chemotherapy on expression of folate receptor-α in ovarian cancer. Cell Oncol. 35, 9-18 (2012).
55. Taylor, R. M., Severns, V., Brown, D. C., Bisoffi, M. & Sillerud, L. O. Prostate cancer targeting motifs: expression of αρβ3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts. Prostate 72, 523-532 (2012).
56. Huo, M. et al. Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG- deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles. Biomaterials 33, 6393-6407 (2012).
57. Xiao, Y. et al. Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy. Nanoscale 4, 7185-7193 (2012).
58. Zhang, J. et al. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models. Mol. Pharmaceut. 7, 1159-1168 (2010).
59. Brabez, N. et al. Synthesis and evaluation of cholecystokinin trimers: a multivalent approach to pancreatic cancer detection and treatment. Bioorg. Med. Chem. Lett. 23, 2422-2425 (2013).
60. Roosenburg, S., Laverman, P., Delft, F. & Boerman, O. Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors. Amino Acids 41, 1049-1058 (2011).
61. Xu, L. et al. Heterobivalent ligands target cell-surface receptor combinations in vivo. Proc. Natl Acad. Sci. USA 109, 21295-21300 (2012).
62. Yang, H. et al. Bombesin analogue-mediated delivery preferentially enhances the cytotoxicity of a mitochondria-disrupting peptide in tumor cells. PLoS ONE 8, e57358 (2013).
63. Zhang, H. et al. Evolution of bombesin conjugates for targeted pet imaging of tumors. PLoS ONE 7, e44046 (2012).
64. Zhou, Z. et al. Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111In-bombesin conjugates for prostate cancer imaging. J. Nuclear Med. 54, 1605-1612 (2013).
65. Hornick, J. R. et al. The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine. Mol. Cancer 9, 298 (2010).
66. Kashiwagi, H. et al. Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol. Cancer 6, 48-59 (2007).
67. Shoghi, K. I. et al. Quantitative receptor-based imaging of tumor proliferation with the sigma-2 ligand [18F] ISO-1. PLoS ONE 8, e74188 (2013).
68. Spitzer, D. et al. Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling. Cancer Res. 72, 201-209 (2012).
69. Wheeler, K. et al. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br. J. Cancer 82, 1223 (2000).
70. Marelli, U. K., Rechenmacher, F., Sobahi, T. R., Mas-Moruno, C. & Kessler, H. Tumor targeting via integrin ligands. Front Oncol. 3, 22 (2013).
71. Chittasupho, C. et al. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur. J. Pharm. Sci. 37, 141-150 (2009).
72. Schr?der, C. et al. Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J. Cancer Res. Clin. Oncol. 137, 1193-1201 (2011).
73. Usami, Y. et al. Intercellular adhesion molecule-1 (ICAM-1) expression correlates with oral cancer progression and induces macrophage/cancer cell adhesion. Int. J. Cancer 133, 568-578 (2013).
74. Papas, M. G. et al. LFA-1 expression in a series of colorectal adenocarcinomas. J. Gastrointest. Cancer 43, 462-466 (2012).
75. Liu, C. et al. Clinical significance of CD24 as a predictor of bladder cancer recurrence. Oncol. Lett. 6, 96-100 (2013).
76. Leamon, C. P. & Low, P. S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl Acad. Sci. 88, 5572-5576 (1991).
77. Chen, S. et al. Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjugate Chem. 21, 979-987 (2010).
78. Tsuji, T., Yoshitomi, H. & Usukura, J. Endocytic mechanism of transferrin-conjugated nanoparticles and the effects of their size and ligand number on the efficiency of drug delivery. Microscopy 62, 341-352 (2013).
79. Zhao, R. et al. A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis. J. Biol. Chem. 284, 4267-4274 (2009).
80. Grandal, M. V. et al. EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis 28, 1408-1417 (2007).
81. Orikawa, Y. et al. Z-360, a novel therapeutic agent for pancreatic cancer, prevents up-regulation of ephrin B1 gene expression and phosphorylation of NR2B via suppression of interleukin-1 β production in a cancer-induced pain model in mice. Mol. Pain 6, 1744-8069 (2010).
82. Wayua, C. & Low, P. S. Evaluation of a cholecystokinin 2 receptor-targeted near-infrared dye for fluorescence-guided surgery of cancer. Mol. Pharm. 11, 468-476 (2014).
83. Van Valckenborgh, E. et al. Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model. Leukemia 19, 1628-1633 (2005).
84. Schmalfeldt, B. et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin. Cancer Res. 7, 2396-2404 (2001).
85. Jeong, Y. et al. Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med. 7, e1000378 (2010).
86. Holbeck, S. et al. Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions. Mol. Endocrinol. 24, 1287-1296 (2010).
87. O'Shannessy, D. J., Somers, E. B., Maltzman, J., Smale, R. & Fu, Y.-S. Folate receptor α (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. SpringerPlus 1, 22 (2012).
88. Chavakis, T., Willuweit, A. K., Lupu, F., Preissner, K. T. & Kanse, S. M. Release of soluble urokinase receptor from vascular cells. Thromb. Haemostasis 86, 686-693 (2001).
89. Wang, L. et al. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. Gynecol. Oncol. 114, 265-272 (2009).
90. Kufe, D. W. Mucins in cancer: function, prognosis and therapy. Nature Rev. Cancer 9, 874-885 (2009).
91. Simons, K. & Fuller, S. D. Cell surface polarity in epithelia. Annu. Rev. Cell Biol. 1, 243-288 (1985).
92. Houri, N., Huang, K. C. & Nalbantoglu, J. The coxsackievirus and adenovirus receptor (CAR) undergoes ectodomain shedding and regulated intramembrane proteolysis (RIP). PLoS ONE 8, e73296 (2013).
93. Jin, Y. et al. Deletion of Cdc42 enhances ADAM17-mediated vascular endothelial growth factor receptor 2 shedding and impairs vascular endothelial cell survival and vasculogenesis. Mol. Cell. Biol. 33, 4181-4197 (2013).
94. Ku, S. K., Han, M. S., Lee, M. Y., Lee, Y. M. & Bae, J. S. Inhibitory effects of oroxylin A on endothelial protein C receptor shedding in vitro and in vivo. BMB Rep. 47, 336-341 (2014).
95. Miller, M. A. et al. ADAM-10 and -17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling. Proc. Natl Acad. Sci. USA 110, 14 (2013).
96. Kelderhouse, L. E. et al. Development of tumor-targeted near infrared probes for fluorescence guided surgery. Bioconjug. Chem. 24, 1075-1080 (2013).
97. Leamon, C. P. et al. Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship. Bioconjug. Chem. 25, 560-568 (2014).
98. Kularatne, S. A., Wang, K., Santhapuram, H.-K. R. & Low, P. S. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol. Pharmaceut. 6, 780-789 (2009).
99. Chittasupho, C. Multivalent ligand: design principle for targeted therapeutic delivery approach. Ther. Delivery 3, 1171-1187 (2012).
100. Lepenies, B., Lee, J. & Sonkaria, S. Targeting C-type lectin receptors with multivalent carbohydrate ligands. Adv. Drug Deliv. Rev. 65, 1271-1281 (2013).
101. Guillemard, V., Nedev, H. N., Berezov, A., Murali, R. & Saragovi, H. U. HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand. DNA Cell Biol. 24, 350-358 (2005).
102. Reubi, J. C. & Schonbrunn, A. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol. Sci. 34, 676-688 (2013).
103. Ivetac, A. & McCammon, J. A. Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach. Chem. Biol. Drug Des. 76, 201-217 (2010).
104. Hashim, Y. M. et al. Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. Mol. Oncol. 8, 956-967 (2014).
105. Adair, J. R., Howard, P. W., Hartley, J. A., Williams, D. G. & Chester, K. A. Antibody-drug conjugates - a perfect synergy. Expert Opin. Biol. Ther. 12, 1191-1206 (2012).
106. Chauhan, V. P., Stylianopoulos, T., Boucher, Y. & Jain, R. K. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu. Rev. Chem. Biomol. Eng. 2, 281-298 (2011).
107. Kim, C. H. et al. Bispecific small molecule-antibody conjugate targeting prostate cancer. Proc. Natl Acad. Sci. USA 110, 17796-17801 (2013).
108. Vlashi, E., Kelderhouse, L. E., Sturgis, J. E. & Low, P. S. Effect of folate-targeted nanoparticle size on their rates of penetration into solid tumors. ACS Nano 7, 8573-8582 (2013).
109. Hashizume, H. et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156, 1363-1380 (2000).
110. Manzoor, A. A. et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res. 72, 5566-5575 (2012).
111. Scott, D. W. & Gascoyne, R. D. The tumour microenvironment in B cell lymphomas. Nature Rev. Cancer 14, 517-534 (2014).
112. Seufferlein, T. et al. Tumor biology and cancer therapy - an evolving relationship. Cell Commun. Signal 7, 7-19 (2009).
113. Minchinton, A. I. & Tannock, I. F. Drug penetration in solid tumours. Nature Rev. Cancer 6, 583-592 (2006).
114. Overall, C. M. & Kleifeld, O. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nature Rev. Cancer 6, 227-239 (2006).
115. Yoo, J. W., Chambers, E. & Mitragotri, S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr. Pharm. Des. 16, 2298-2307 (2010).
116. Gabizon, A. et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54, 987-992 (1994).
117. Huang, J. et al. Effects of nanoparticle size on cellular uptake and liver MRI with polyvinylpyrrolidone-coated iron oxide nanoparticles. ACS Nano 4, 7151-7160 (2010).
118. Sadauskas, E. et al. Kupffer cells are central in the removal of nanoparticles from the organism. Part Fibre Toxicol. 4, 10 (2007).
119. Wang, B., Galliford, C., & Low, P. S. Guiding principles in the design of ligand-targeted nanomedicines. Nanomedicine 9, 313-330 (2014).
120. Fisher, R. E. et al. Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J. Nucl. Med. 49, 899-906 (2008).
121. Briasoulis, E. et al. Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the european organization for research and treatment of cancer early clinical studies group. J. Clin. Oncol. 18, 3535-3544 (2000).
122. Sanna, V., Pala, N. & Sechi, M. Targeted therapy using nanotechnology: focus on cancer. Int. J. Nanomed. 9, 467-483 (2014).
123. Leamon, C. P. et al. Synthesis and biological evaluation of EC20: a new folate-derived, 99mTc-based radiopharmaceutical. Bioconjugate Chem. 13, 1200-1210 (2002).
124. Yang, J. J., Kularatne, S. A., Chen, X., Low, P. S. & Wang, E. Characterization of in vivo disulfide-reduction mediated drug release in mouse kidneys. Mol. Pharmaceut. 9, 310-317 (2011).
125. Kularatne, S. A., Zhou, Z., Yang, J., Post, C. B. & Low, P. S. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted 99mTc-radioimaging agents. Mol. Pharm. 6, 790-800 (2009).
126. Granier, S. et al. Structure of the δ-opioid receptor bound to naltrindole. Nature 485, 400-404 (2012).
127. Nakamura, Y. et al. "Click-made" biaryl-linker improving efficiency in protein labelling for the membrane target protein of a bioactive compound. Org. Biomol. Chem. 9, 83-85 (2011).
128. Tamura, S. et al. Triazoyl-phenyl linker system enhancing the aqueous solubility of a molecular probe and its efficiency in affinity labeling of a target protein for jasmonate glucoside. Bioorg. Med. Chem. Lett. 23, 188-193 (2013).
129. Mikuni, K. et al. In vivo antitumor activity of novel water-soluble taxoids. Biol. Pharm. Bull. 31, 1155-1158 (2008).
130. Pinhassi, R. I. et al. Arabinogalactan?folic acid?drug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells. Biomacromolecules 11, 294-303 (2009).
131. Vlahov, I. R. & Leamon, C. P. Engineering folate-drug conjugates to target cancer: from chemistry to clinic. Bioconjugate Chem. 23, 1357-1369 (2012).
132. Vlahov, I. R. et al. Carbohydrate-based synthetic approach to control toxicity profiles of folate?drug conjugates. J. Org. Chem. 75, 3685-3691 (2010).
133. Du, C. et al. Synthesis and evaluation of a folate-linked anti-cancer prodrug. International Conference on Biomedical Engineering and Biotechnology (iCBEB) http://dx.doi.org/10.1109/iCBEB.2012.388 (2012).
134. Endocyte Inc. Conjugates containing hydrophilic spacers. WO/2009/002993 (2008).
135. Leamon, C. P. et al. Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications. J. Pharmacol. Exp. Ther. 336, 336-343 (2011).
136. Wadhwa, S. & Mumper, R. J. Polypeptide conjugates of d-penicillamine and idarubicin for anticancer therapy. J. Controlled Release 158, 215-223 (2012).
137. Yang, J., Chen, H., Vlahov, I. R., Cheng, J.-X. & Low, P. S. Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates. J. Pharmacol. Exp. Ther. 321, 462-468 (2007).
138. Abu Ajaj, K. et al. Comparative evaluation of the biological properties of reducible and acid-sensitive folate prodrugs of a highly potent doxorubicin derivative. Eur. J. Cancer 48, 2054-2065 (2012).
139. Kigawa, J. et al. Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer. Cancer 82, 697-702 (1998).
140. Shao, L.-H. et al. Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis. Cancer 118, 2986-2996 (2012).
141. Liang, L. et al. Novel cathepsin B-sensitive paclitaxel conjugate: higher water solubility, better efficacy and lower toxicity. J. Controlled Release 160, 618-629 (2012).
142. Barthel, B. L. et al. Synthesis and biological characterization of protease-activated prodrugs of doxazolidine. J. Med. Chem. 55, 6595-6607 (2012).
143. Ojima, I. Guided molecular missiles for tumor-targeting chemotherapy - case studies using the second-generation taxoids as warheads. Accounts Chem. Res. 41, 108-119 (2007).
144. Erez, R., Segal, E., Miller, K., Satchi-Fainaro, R. & Shabat, D. Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel. Bioorg. Med. Chem. 17, 4327-4335 (2009).
145. Weinstain, R., Segal, E., Satchi-Fainaro, R. & Shabat, D. Real-time monitoring of drug release. Chem. Commun. 46, 553-555 (2010).
146. Little, A. S., Balmanno, K., Sale, M. J., Smith, P. D. & Cook, S. J. Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. Biochem. Soc. Trans. 40, 73-78 (2012).
147. Montagut, C. et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853-4861 (2008).
148. Cao, X. et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother. Pharmacol. 59, 495-505 (2007).
149. Liu, Y. et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol. Cancer Ther. 11, 1672-1682 (2012).
150. Seltzer, M. J. et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 70, 8981-8987 (2010).
151. Simpson, C. D. et al. Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. Cancer Res. 69, 2739-2747 (2009).
152. Chan, S.-H. et al. Reevesioside F induces potent and efficient anti-proliferative and apoptotic activities through Na+/K+-ATPase α3 subunit-involved mitochondrial stress and amplification of caspase cascades. Biochem. Pharmacol. 86, 1564-1575 (2013).
153. Coloff, J. L. et al. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res. 71, 5204-5213 (2011).
154. Guo, W. et al. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J. Cancer Res. Clin. Oncol. 137, 65-72 (2011).
155. Shi, H. S. et al. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci. 101, 1447-1453 (2010).
156. Sakurai, Y. et al. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA. Biomaterials 32, 5733-5742 (2011).
157. Lin, N. et al. A novel system enhancing the endosomal escapes of peptides promotes Bak BH3 peptide inducing apoptosis in lung cancer A549 cells. Targeted Oncol. 9, 163-170 (2013).
158. Hatakeyama, H. et al. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J. Controlled Release 139, 127-132 (2009).
159. Malamas, A. S., Gujrati, M., Kummitha, C. M., Xu, R. & Lu, Z.-R. Design and evaluation of new pH-sensitive amphiphilic cationic lipids for siRNA delivery. J. Controlled Release 171, 296-307 (2013).
160. Sakurai, Y. et al. Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system. Biol. Pharm. Bull. 32, 928-932 (2009).
161. Kim, H., Lee, D., Kim, J., Kim, T.-i. & Kim, W. J. Photothermally triggered cytosolic drug delivery via endosome disruption using a functionalized reduced graphene oxide. ACS Nano 7, 6735-6746 (2013).
162. Nelson, C. E. et al. Balancing cationic and hydrophobic content of pegylated sirna polyplexes enhances endosome escape, stability, blood circulation time, and bioactivity in vivo. ACS Nano 7, 8870-8880 (2013).
163. Kalli, K. R. et al. Folate receptor α as a tumor target in epithelial ovarian cancer. Gynecol. Oncol. 108, 619-626 (2008).
164. Cagle, P. T., Zhai, Q. J., Murphy, L. & Low, P. S. Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folate-linked therapeutic agents. Arch. Pathol. Lab. Med. 137, 241-244 (2012).
165. Yang, J., Vlashi, E. & Low, P. Folate-linked drugs for the treatment of cancer and inflammatory diseases. Subcell. Biochem. 56, 163-179 (2012).
166. Naumann, R. W. et al. PRECEDENT: a randomized Phase II trial comparing vintafolide (Ec145) and PEGylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 31, 4400-4406 (2013).
167. Leamon, C. P. et al. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol. Pharmaceut. 4, 659-667 (2007).
168. Covello, K. et al. Preclinical pharmacology of epothilone-folate conjugate BMS-753493, a tumor-targeting agent selected for clinical development. AACR Meeting Abstracts [online], http://www. aacrmeetingabstracts.org/cgi/content/meeting-abstract/2008/1-Annual-Meeting/2326 (2008).
169. Gokhale, M., Thakur, A. & Rinaldi, F. Degradation of BMS-753493, a novel epothilone folate conjugate anticancer agent. Drug Dev. Ind. Pharm. 39, 1315-1327 (2013).
170. Dhawan, D. et al. Targeting folate receptors to treat invasive urinary bladder cancer. Cancer Res. 73, 875-884 (2013).
171. Kumar, P. et al. Design, synthesis, and preliminary biological evaluation of 6-O-glucose-azomycin adducts for diagnosis and therapy of hypoxic tumors. J. Med. Chem. 55, 6033-6046 (2012).
172. Goff, R. D. & Thorson, J. S. Assessment of chemoselective neoglycosylation methods using chlorambucil as a model. J. Med. Chem. 53, 8129-8139 (2010).
173. Miot-Noirault, E. et al. Preclinical investigation of tolerance and antitumour activity of new fluorodeoxyglucose-coupled chlorambucil alkylating agents. Invest. New Drugs 29, 424-433 (2011).
174. Ciuleanu, T. E. et al. A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur. J. Cancer 45, 1589-1596 (2009).
175. D'Amato, G. et al. Preliminary efficacy and safety results of glufosfamide (GLU) in relapsed soft tissue sarcoma: results of a phase II trial. ASCO Meeting Abstracts 26 (Suppl. 15), 10591 (2008).
176. Corti, A. et al. Targeted drug delivery and penetration into solid tumors. Med. Res. Rev. 32, 1078-1091 (2012).
177. Di Matteo, P. et al. NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells. Br. J. Cancer 109, 360-369 (2013).
178. Lin, N. U., et al. Abstract P3-12-04: a phase 2, multi-center, open label study evaluating the efficacy and safety of GRN1005 alone or in combination with trastuzumab in patients with brain metastases from breast cancer. Cancer Res. 72, P3-12-04 (2012).
179. Palmer, E., Scott, J. & Symanowski, J. Reliability and reproducibility of etarfolatide as a folate receptor (FR)-targeted diagnostic imaging agent. J. Nucl Med Meeting Abstracts 54 (Suppl. 2), 400 (2013).
180. Maurer, A. H. et al. Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging. J. Nucl. Med. 55, 701-704 (2014).
181. van Dam, G. M. et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nature Med. 17, 1315-1319 (2011).
182. Lesche, R. et al. Preclinical evaluation of BAY 1075553, a novel F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur. J. Nucl. Med. Mol. Imag. 17, 17 (2013).
183. Banerjee, S. R. et al. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J. Med. Chem. 53, 5333-5341 (2010).
184. Chen, Y. et al. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)- pentanedioic acid, [18F]DCFPYL, a PSMA-based PET imaging agent for prostate cancer. Clin. Cancer Res. 17, 7645-7653 (2011).
185. Cho, S. Y. et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J. Nucl. Med. 53, 1883-1891 (2012).
186. Sanna, V. & Sechi, M. Nanoparticle therapeutics for prostate cancer treatment. Maturitas 73, 27-32 (2012).
187. Reddy, J. A. et al. Abstract 2145: PSMA-specific anti-tumor activity of the targeted-tubulysin conjugate, EC1169. Cancer Res. 73, 2145 (2013).
188. Sounness, B. D. & Schembri, G. P. 68Ga-dotatate avid medullary thyroid cancer with occult liver metastases. Clin. Nucl. Med. 39, 87-90 (2013).
189. Klinaki, I., Al-Nahhas, A., Soneji, N. & Win, Z. 68Ga DOTATATE PET/CT uptake in spinal lesions and MRI correlation on a patient with neuroendocrine tumor: potential pitfalls. Clin. Nucl. Med. 38, e449-e453 (2013).
190. Haug, A. R. et al. Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. Radiology 270, 517-525 (2013).
191. Gayana, S., Mittal, B. R., Bhattacharya, A., Radotra, B. D. & Gupta, A. K. 68Ga-DOTATATE PET/CT imaging in carotid body tumor. Clin. Nucl. Med. 38, e191-e193 (2013).
192. Dobson, R. et al. Treatment of orbital metastases from a primary midgut neuroendocrine tumor with peptide-receptor radiolabeled therapy using 177lutetium-DOTATATE. J. Clin. Oncol. 31, e272-e275 (2013).
193. Kulkarni, H. R., Schuchardt, C. & Baum, R. P. Peptide receptor radionuclide therapy with 177Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient. Recent Results Cancer Res. 194, 551-559 (2013).
194. Christ, E., Wild, D. & Reubi, J. C. Glucagonlike peptide-1 receptor: an example of translational research in insulinomas: a review. Endocrinol. Metabolism Clin. North Amer. 39, 791-800 (2010).
195. Beer, A. J. & Schwaiger, M. PET of αvβ3-integrin and αvβ5-integrin expression with 18F-fluciclatide for assessment of response to targeted therapy: ready for prime time? J. Nucl. Med. 52, 335-337 (2011).
196. Battle, M. R., Goggi, J. L., Allen, L., Barnett, J. & Morrison, M. S. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVβ3-integrin and αVβ5 -integrin imaging agent. J. Nucl. Med. 52, 424-430 (2011).
197. Tomasi, G., Kenny, L., Mauri, F., Turkheimer, F. & Aboagye, E. O. Quantification of receptor-ligand binding with [18F]fluciclatide in metastatic breast cancer patients. Eur. J. Nucl. Med. Mol. Imag. 38, 2186-2197 (2011).
198. Guo, N. et al. Quantitative analysis and comparison study of [18F]AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 using a reference tissue model. PLoS ONE 7, 18 (2012).
199. Gao, H. et al. PET imaging of angiogenesis after myocardial infarction/reperfusion using a one-step labeled integrin-targeted tracer 18F-AlF-NOTA-PRGD2. Eur. J. Nucl. Med. Mol. Imag. 39, 683-692 (2012).
200. Lang, L. et al. Comparison study of [18F]FAl- NOTA-PRGD2, [18F]FPPRGD2, and [68Ga] Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug. Chem. 22, 2415-2422 (2011).
201. Roivainen, A. et al. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J. Nucl. Med. 54, 867-872 (2013).
202. Ray Banerjee, S. et al. Effect of chelators on the pharmacokinetics of 99mTc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). J. Med. Chem. 56, 6108-6121 (2013).
203. Chen, H. et al. Folate-modified gold nanoclusters as near-infrared fluorescent probes for tumor imaging and therapy. Nanoscale 4, 6050-6064 (2012).
204. He, W. et al. Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int. J. Cancer 123, 1968-1973 (2008).
205. He, W., Wang, H., Hartmann, L. C., Cheng, J.-X. & Low, P. S. In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proc. Natl Acad. Sci. 104, 11760-11765 (2007).
206. LoRusso, P. M. et al. Phase I study of folate conjugate EC145 (vintafolide) in patients with refractory solid tumors. J. Clin. Oncol. 30, 4011-4016 (2012).
207. Amato, R. J., Shetty, A., Lu, Y., Ellis, R. & Low, P. S. A Phase I study of folate immune therapy (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) in patients with renal cell carcinoma. J. Immunother. 36, 268-275 (2013).
208. Wang, R. E., Niu, Y., Wu, H., Hu, Y. & Cai, J. Development of NGR-based anti-cancer agents for targeted therapeutics and imaging. Anticancer Agents Med. Chem. 12, 76-86 (2012).
209. Regina, A. et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol. 155, 185-197 (2008).
210. Mahalingam, S. M., Kularatne, S. A., Roy, J. & Low, P. S. MEDI-329 evaluation of pteroyl-amino acid- NIR dye conjugates for tumor targeted fluorescence guided surgery. American Chemical Society [online], http://abstracts.acs.org//chem/246nm/program/view.php?pub-num=329&par=MEDI (2013).
211. Barrett, J. A. et al. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J. Nucl. Med. 54, 380-387 (2013).
212. Hillier, S. M. et al. 99MTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J. Nuclear Med. 54, 1369-1376 (2013).
213. Sandstrom, M. et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J. Nucl. Med. 54, 1755-1759 (2013).